|
🐜
|
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
36 auth.
A. Ribas,
I. Puzanov,
R. Dummer,
D. Schadendorf,
O. Hamid,
C. Robert,
F. Hodi,
J. Schachter,
A. Pavlick,
Karl D. Lewis,
L. Cranmer,
C. U. Blank,
S. O'Day,
P. Ascierto,
April K.S. Salama,
...
K. Margolin,
C. Loquai,
Thomas Eigentler,
T. Gangadhar,
M. Carlino,
S. Agarwala,
S. Moschos,
J. Sosman,
S. Goldinger,
R. Shapira-Frommer,
R. Gonzalez,
J. M. Kirkwood,
J. Wolchok,
A. Eggermont,
Xiaoyun Li,
W. Zhou,
Adriane M Zernhelt,
Joy Lis,
S. Ebbinghaus,
S. Kang,
A. Daud
|
10 |
2015 |
10
🐜
|
|
🐜
|
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018
17 auth.
Jürgen C. Becker,
Thomas Eigentler,
Bernhard Frerich,
T. Gambichler,
S. Grabbe,
Ulrike Höller,
Bernhard Klumpp,
Carmen Loquai,
Albrecht Krause‐Bergmann,
Urs Müller‐Richter,
...
C. Pföhler,
S. Schneider‐Burrus,
Andreas Stang,
P. Terheyden,
Selma Ugurel,
Johannes Veith,
Cornelia Mauch
|
5 |
2019 |
5
🐜
|
|
🐜
|
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
20 auth.
A. Hauschild,
Jessica C Hassel,
M. Ziemer,
Piotr Rutkowski,
F. Meier,
L. Flatz,
C. Gaudy-Marqueste,
M. Santinami,
F. Russano,
I. von Wasielewski,
...
Thomas Eigentler,
M. Maio,
I. Zalaudek,
S. Haferkamp,
P. Quaglino,
P. Ascierto,
Claus Garbe,
C. Robert,
D. Schadendorf,
K. Kähler
|
3 |
2024 |
3
🐜
|
|
🐜
|
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
35 auth.
C. Ertl,
T. Ruf,
Dirk Mentzer,
Mingzi Kong,
Rafaela Kramer,
M. V. Bergwelt-Baildon,
M. Subklewe,
D. Tomsitz,
P. Ascierto,
R. Dummer,
Helen Gogas,
Celeste Lebbe,
Georgina V Long,
Grant A Mcarthur,
T. Neilan,
...
Antoni Ribas,
C. Robert,
D. Schadendorf,
Lisa Zimmer,
Thomas Eigentler,
S. Grabbe,
A. Forschner,
K. Kähler,
Valeria Milani,
Claudia Pföhler,
J. Hassel,
Ralf Gutzmer,
Carmen Loquai,
B. Routy,
A. J. Furness,
Christian U Blank,
J. Wolchok,
L. E. French,
A. Hauschild,
Lucie M. Heinzerling
|
2 |
2023 |
2
🐜
|
|
🐜
|
Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study
14 auth.
E. Livingstone,
Thomas Eigentler,
Christine Windemuth-Kieselbach,
Axel Hauschild,
Rainer Rompel,
Uwe Trefzer,
Dorothee Nashan,
Katharina Kilian,
D. Debus,
K. Kähler,
...
A. Mauerer,
K. Möllenhoff,
E. Dippel,
D. Schadendorf
|
2 |
2015 |
2
🐜
|
|
🐜
|
S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“– update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care
50 auth.
M. Heppt,
Ulrike Leiter,
Theresa Steeb,
Mareike Alter,
T. Amaral,
A. Bauer,
F. Bechara,
Jürgen C. Becker,
E. Breitbart,
Helmut Breuninger,
T. Diepgen,
T. Dirschka,
Thomas Eigentler,
A. K. Stephan El Gammal,
Moritz Felcht,
...
Michael J. Flaig,
M. Follmann,
Klaus Fritz,
S. Grabbe,
R. Greinert,
Ralf Gutzmer,
A. Hauschild,
U. Hillen,
Stephan Ihrler,
Swen Malte John,
Lukas Kofler,
O. Koelbl,
Albrecht Krause‐Bergmann,
Klaus Kraywinkel,
Steffen Krohn,
T. Langer,
Carmen Loquai,
Christoph R Löser,
Peter Mohr,
D. Nashan,
Monika Nothacker,
Christina Pfannenberg,
C. Salavastru,
L. Schmitz,
E. Stockfleth,
R. Szeimies,
Claas Ulrich,
S. Voelter‐Mahlknecht,
D. Vordermark,
Michael Weichenthal,
J. Welzel,
K. Wermker,
Susanne Wiegand,
Claus Garbe,
C. Berking
|
2 |
2023 |
2
🐜
|
|
🐜
|
Improving assessment of lesions in longitudinal CT scans: a bi-institutional reader study on an AI-assisted registration and volumetric segmentation workflow
16 auth.
Alessa Hering,
Max Westphal,
Annika Gerken,
Haidara Almansour,
Michael Maurer,
Benjamin Geisler,
Temke Kohlbrandt,
Thomas Eigentler,
Teresa Amaral,
N. Lessmann,
...
S. Gatidis,
Horst K. Hahn,
Konstantin Nikolaou,
Ahmed E. Othman,
J. Moltz,
Felix Peisen
|
2 |
2024 |
2
🐜
|
|
🐜
|
S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention
50 auth.
Ulrike Leiter,
M. Heppt,
Theresa Steeb,
Mareike Alter,
T. Amaral,
A. Bauer,
F. Bechara,
Jürgen C. Becker,
E. Breitbart,
Helmut Breuninger,
T. Diepgen,
T. Dirschka,
Thomas Eigentler,
A. K. Stephan ElGammal,
Moritz Felcht,
...
Michael J. Flaig,
M. Follmann,
Klaus Fritz,
S. Grabbe,
R. Greinert,
Ralf Gutzmer,
A. Hauschild,
U. Hillen,
Stephan Ihrler,
Swen Malte John,
Lukas Kofler,
O. Koelbl,
Albrecht Krause‐Bergmann,
Klaus Kraywinkel,
Steffen Krohn,
T. Langer,
Carmen Loquai,
Christoph R Löser,
Peter Mohr,
D. Nashan,
Monika Nothacker,
Christina Pfannenberg,
C. Salavastru,
L. Schmitz,
E. Stockfleth,
R. Szeimies,
Claas Ulrich,
S. Voelter‐Mahlknecht,
D. Vordermark,
Michael Weichenthal,
J. Welzel,
K. Wermker,
Susanne Wiegand,
Claus Garbe,
C. Berking
|
2 |
2023 |
2
🐜
|
|
🐜
|
Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy
9 auth.
Felix Peisen,
Annika Gerken,
Isabel Dahm,
Konstantin Nikolaou,
Thomas Eigentler,
Teresa Amaral,
...
J. Moltz,
Ahmed E. Othman,
S. Gatidis
|
1 |
2024 |
1
🐜
|
|
🐜
|
Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.
20 auth.
Pierluigi Porcu,
M. Bagot,
C. Ram-Wolff,
Youn H. Kim,
A. Huen,
Stéphane Dalle,
B. Poligone,
N. Mehta-Shah,
A.B. Duval Modeste,
P. Zinzani,
...
F. S. H. Woei-A-Jin,
Thomas Eigentler,
Andrea Combalia,
L. Sokol,
M. Battistella,
A. Gru,
Hélène Moins Teisserenc,
Julien Viotti,
C. Paiva,
Agnes boyer Chammard
|
0 |
2024 |
0
🐜
|
